Press release
Antibody-Drug Conjugates Market to Reach US$ 30.42 Billion by 2033 at 11.2% CAGR, Driven by Precision Oncology and Targeted Cancer Therapies | DataM Intelligence
Antibody Drug Conjugates Market
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/antibody-drug-conjugates-market?jd
North America (Largest Region) - Key Industry Developments
North America dominates the ADC market, accounting for 44.3% share in 2024, supported by strong oncology R&D, favorable regulatory pathways, and high adoption of innovative cancer therapies.
✅ November 2025: AstraZeneca and Daiichi Sankyo expanded clinical development programs for Enhertu across multiple solid tumor indications in the U.S.
✅ October 2025: Pfizer Inc. and Gilead Sciences, Inc. strengthened ADC manufacturing and commercialization capabilities to meet rising demand in oncology centers.
✅ September 2025: F. Hoffmann-La Roche Ltd. advanced lifecycle management strategies for Kadcyla and Polivy through combination therapy trials.
Asia-Pacific - Key Industry Developments
Asia-Pacific holds 17.6% of the global ADC market in 2024 and continues to grow rapidly due to expanding cancer patient populations, increasing clinical trial activity, and improving access to advanced therapies.
✅ November 2025: RemeGen Co., Ltd. and Astellas Pharma Inc. advanced regional clinical programs for novel ADCs targeting breast and gastric cancers.
✅ October 2025: Takeda Pharmaceutical Company Ltd. expanded oncology research collaborations across Japan and China to accelerate ADC pipeline development.
✅ September 2025: Regional biotech companies increased investments in ADC manufacturing infrastructure to support domestic and global supply.
Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=antibody-drug-conjugates-market
(Purchase 2 or more Reports and get 50% Discount)
Market Segmentation Analysis
-By Application: Breast Cancer Leads Market Share
The breast cancer segment is expected to hold 39.3% of the global ADC market in 2024, driven by strong clinical outcomes of HER2-targeted ADCs such as Enhertu and Kadcyla.
-By Target Type: HER2 Antibodies Dominate
HER2 antibodies represent a dominant target type, supported by expanding indications across breast, gastric, and lung cancers.
-By Technology Type: Linker and Payload Innovation Drives Growth
Advancements in linker stability and potent payloads are improving therapeutic index and expanding ADC applicability across tumor types.
-By End-User: Hospitals and Cancer Centers Lead Adoption
Hospitals and specialized cancer centers dominate ADC usage due to access to advanced oncology care and infusion infrastructure.
Regional Insights
North America leads the global ADC market due to strong pharmaceutical innovation, high healthcare spending, and rapid regulatory approvals. Asia-Pacific is emerging as a high-growth region, driven by increasing cancer prevalence, expanding clinical research, and improving access to targeted therapies. Europe continues to demonstrate steady growth supported by established oncology treatment frameworks and reimbursement systems.
Growth Drivers:
1. Rising Global Cancer Incidence
2. Increasing Demand for Targeted and Precision Oncology Therapies
3. Technological Advancements in ADC Linker and Payload Design
4. Expanding Clinical Pipeline and Regulatory Approvals
5. Strategic Pharma-Biotech Collaborations
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/antibody-drug-conjugates-market?jd
Key Players:
The Antibody-Drug Conjugates Market includes leading companies such as Pfizer, Inc., AstraZeneca, GSK plc, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Ltd., Gilead Sciences, Inc., ADC Therapeutics, Astellas Pharma Inc., ImmunoGen, Inc., ACROBiosystems, and RemeGen Co., Ltd.
Key Highlights (Top 5 Key Players):
1. AstraZeneca & Daiichi Sankyo lead the market with Enhertu's expanding oncology indications.
2. Pfizer Inc. focuses on next-generation ADC pipeline development and manufacturing scale-up.
3. Gilead Sciences, Inc. strengthens its oncology portfolio through Trodelvy expansion.
4. F. Hoffmann-La Roche Ltd. maintains strong ADC leadership with Kadcyla and Polivy.
5. ImmunoGen, Inc. plays a key role in advancing ADC technology platforms.
Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply-Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antibody-Drug Conjugates Market to Reach US$ 30.42 Billion by 2033 at 11.2% CAGR, Driven by Precision Oncology and Targeted Cancer Therapies | DataM Intelligence here
News-ID: 4325121 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Cell Dissociation Market to Reach US$ 915.8 Million by 2033 at 8.7% CAGR; Rising …
The Global Cell Dissociation Market reached US$ 430.6 million in 2024 and is expected to reach US$ 915.8 million by 2033, growing at a CAGR of 8.7% during the forecast period 2025-2033. The market is expanding steadily due to increasing demand for cell-based research, rising adoption of stem cell and regenerative medicine therapies, and growing investment in biotechnology and pharmaceutical R&D. The surge in cancer research, immunotherapy development, and personalized…
Food Waste Management Market to Reach US$ 136.2 Billion by 2032, Driven by Susta …
According to DataM Intelligence, the global food waste management market reached US$ 69.8 billion in 2024 and is expected to reach US$ 136.2 billion by 2032, growing at a CAGR of 8.7% during the forecast period 2025-2032. Market growth is driven by rising global food waste volumes, stringent environmental regulations, increasing adoption of circular economy models, and growing investments in sustainable waste processing technologies such as anaerobic digestion and recycling.…
Stem Cell Therapy Market to Reach US$ 45.69 Billion by 2033 at 12.7% CAGR; Advan …
The Global Stem Cell Therapy Market reached US$ 16.44 billion in 2024 and is expected to reach US$ 45.69 billion by 2033, growing at a CAGR of 12.7% during the forecast period 2025-2033. The market has shown consistent growth momentum, increasing from US$ 15.13 billion in 2022 to US$ 15.73 billion in 2023, reflecting rising clinical adoption and expanding research activity. Growth is being driven by increasing prevalence of chronic…
Stainless Steel Wire and Wire Rod Market to Reach US$ 11.24 Billion by 2032, Dri …
According to DataM Intelligence, the global stainless steel wire and wire rod market reached US$ 6,600.84 million in 2024 and is expected to reach US$ 11,237.22 million by 2032, growing at a CAGR of 7.0% during the forecast period 2025-2032. Market growth is supported by rising demand from construction, automotive, energy & power, and industrial manufacturing sectors, along with increasing adoption of corrosion-resistant and high-strength stainless steel materials.
Get a…
More Releases for ADC
ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments.
Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion
Key…
With Knockout ADC Innovations, Creative Biolabs Took Center Stage at the 2024 Wo …
Creative Biolabs wrapped up a successful show at the 15th Annual World ADC San Diego in the beginning of November, where its third year of participation, highlighting its dedication to the advancement of antibody-drug conjugate (ADC) technology.
New York, USA - November 13, 2024 - Creative Biolabs seized the spotlight at Booth 313 by offering groundbreaking solutions across the entire ADC development spectrum, which demonstrate their unrivaled expertise and dedication to…
Showing Off Their ADC Game: Creative Biolabs Hits the 15th Annual World ADC Summ …
From November 4, Creative Biolabs will be back at the 15th Annual World ADC Summit in San Diego, marking its fourth year at the leading global gathering featuring innovative conjugates.
New York, USA - November 6, 2024 - Creative Biolabs invites all ADC enthusiasts, from new entrants to seasoned experts, to explore its comprehensive suite of ADC solutions and experience the latest in antibody-drug conjugate (ADC) innovation at Booth #313.
Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg
"2023…
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer treatment.
On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by…
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Succe …
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Successive Approximation ADC, Delta-sigma ADC, and Others (Pipelined/Flash ADC)), and Application (Consumer Electronics and Industrial) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Full Report : https://www.alliedmarketresearch.com/analog-to-digital-converters-market
Increasing disposable income and technological advancements supplement the analog-to-digital converters market. However, complex design of the ADC hampers this market growth. On the other hand, encouragement in digitization of work processes by government in emerging economies,…
Global Data Converters Market Report 2017 (Analog to Digital Converter, Current …
The research report titled Global Data Converters Sales Market Report 2017 market size and forecast and overview on current market trends.
This report studies sales (consumption) of Global Data Converters Market 2017, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering
National Semiconductor
Nippon Precision Circuits Inc
Micro Analog systems
Microchip Technology.
TelCom Semiconductor, Inc
Vishay Siliconix
Texas…
